Gene Therapy for Brain Tumors

Brain Pathology

Volumn 5, Issue 4, 1995, Pages 345-381

  Kramm, Christof M ^a,b,f   Sena‐Esteves, Miguel ^a,f   Barnett, Faith H ^a,c,f   Rainov, Nikolai G ^a,d,f   Schuback, Deborah E ^a,f   Yu, John S ^a,f   Pechan, Peter A ^a,f   Paulus, Werner ^a,e,f   Chiocca, E Antonio ^a,f   Breakefield, Xandra O ^a,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; CYCLOPHOSPHAMIDE; FLUCYTOSINE; GANCICLOVIR; PRODRUG; THYMIDINE KINASE; TIOGUANINE; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL TISSUE; BRAIN TUMOR; CONTROLLED STUDY; GENE THERAPY; GLIOBLASTOMA; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; NONHUMAN; RAT; REVIEW; TRANSGENE;

ANTIBODY FORMATION; BRAIN NEOPLASMS; CLINICAL TRIALS; GENE THERAPY; GENETIC VECTORS; HUMAN; NEOVASCULARIZATION, PATHOLOGIC; SUPPORT, NON-U.S. GOV'T; TRANSGENES; VIRUSES;

EID: 0028886564     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1995.tb00615.x     Document Type: Article

References (348)

1. Pharmacokinetics, biodistribtution and stability of oligodeoxynucleotide phosphothiorates in mice
2. Polymeric sustained delivery of antisense oligonucleotides for the treatment of brain cancer
3. Transfer of a foreign gene into the brain using adenovirus vectors
4. A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane‐spanning protein and confers susceptibility to virus infection
5. DNA‐damaging agents greatly increase the transduction of non‐dividing cells by adeno‐associated virus vectors
6. Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats
7. ORDA reports. Recombinant DNA Advisory Committee (RAC). Data management report‐December 1994
8. Gene targeting in normal somatic cells: inctivation of the interferon‐gamma receptor in myoblasts
9. Negative effects of wild‐type p53 and s‐Myc on cellular growth and tumorigenicity of glioma cells
10. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Echerichia coli cytosine deaminase
11. Stereotatic delivery of a recombinant adenovirus into a C6 glioma cell line in a rat brain tumor model
12. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors
13. Granulocyte‐macrophage colony‐stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients
14. Novel (E)‐5‐(2‐iodovinyl)‐2'‐deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors
15. Thymidine kinase‐mediated killing of rat brain tumors
16. Development of anti‐tumor immunity following thymidine kinase‐mediated killing of experimental brain tumors
17. Herpes simplex virus genomes in human nervous sytem tissues analyzed by polymerase chain reaction
18. Expression from the adeno‐associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein
19. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region
20. Pre‐early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs
21. + mouse teratocarcinoma and hybrid cells
22. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV‐tk retroviral gene therapy
23. Gene amplification in malignant human gliomas: clinical and histopathologic aspects
24. ICP34.5 mutants of herpes simplex virus type 1 strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cell cultures
25. Expression and interactions of human adenovirus oncoproteins
26. The retroviral vector. Replication cycle and safety considerations for retrovirus‐mediated gene therapy
27. Long‐term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene
28. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase
29. Gene transfer into experimental brain tumors mediated by adenovirus, herpes‐simplex‐virus (HSV), and retrovirus vectors
30. A nucleoprotein complex mediates the integration of retroviral DNA
31. Endocytosis is regulated by protein kinase A, but not protein kinase C in a secretory epithelial cell line
32. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas
33. Herpes simplex virus for gene delivery to neurons
34. A nuclear localization signal within HIV‐1 matrix protein that governs infection of non‐dividing cells
35. Immunobiology of human gliomas
36. Antisense technology for cancer therapy: does it make sense
37. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides
38. Synthetic retrotransposon vectors for gene therapy
39. Infection with a transforming growth factor alpha anti‐sense retroviral expression vector reduces the in vitro growth and transformation of a human colon cancer cell line
40. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma
41. Long‐term survival in patients with glioblastoma multiforme
42. Suppression of acute lymphoblastic leukemia by the human p53 gene
43. Early events in the interaction of adenoviruses with HeLa cells. 3. Relationship between an ATPase activity in nuclear envelopes and transfer of core material: a hypothesis
44. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus‐mediated gene transfer in vivo
45. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P‐450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy
46. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by tissue bombardment
47. Cytoreductive effects of anti‐transferrin receptor immunotoxin in a multicellular tumor spheroid model
48. Mapping of herpes simplex virus‐1 neurovirulence to gamma‐1 34.5, a gene nonessential for growth in culture
49. The gamma I (34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neurons
50. Cell targeting with retroviral vector particles containing antibody‐envelope fusion proteins
51. Cloning of two genetically transmitted moloney leukemia proviral genomes: correlation between biological activity of the cloned DNA and viral genome activation in the animal
52. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation
53. Retroviridae and their replication
54. Brain tumors in children
55. Epidermal growth factor receptor gene and its transcripts in glioblastomas
56. Pharmacology of cyclophosphamide and metabolites
57. Alkylating agents and platinum compounds
58. Gene therapy for B cell lymphoma in a SCID mouse model using an immunoglobulin‐regulated diphtheria toxin gene delivered by a novel adenovirus‐polylysine conjugate
59. Efficient episomal expression vector for human transitional carcinoma cells
60. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
61. Biology of adeno‐associated virus
62. In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors
63. Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system
64. Local delivery of beta‐nerve growth factor (B‐NGF) to the neostriatum using transgenic astrocytes: effects on co‐grafted adrenal chromaffin cells in the 6‐OHDA lesioned rat model of Parkinson disease
65. Gene transfer to respiratory epithelial cells via the receptor‐mediated endocytosis pathway
66. High Efficiency gene transfer mediated by adenovirus‐polylysine‐DNA complexes
67. Gene therapy via primary myoblasts: long‐term expression of factor IX protein following transplantation in vivo
68. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges
69. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector
70. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediateearly regulatory protein ICP4
71. Genetic delivery of enzymes for cancer therapy
72. Gap junctions in the brain: where, what type, how many and why
73. The fms‐like tyrosine kinase, a receptor for vascular endothelial growth factor
74. Amplification of the c‐erb‐B oncogene is associated with malignancy in primary tumors of neuroepithelial tissue
75. Transport of 5‐fluorouracil and uracil into human erythrocytes
76. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
77. Gene therapy of rat gliomas using adenovirus vector‐mediated transduction of the cytosine deaminase gene followed by treatment with 5‐fluorocytosine
78. Phosphorothioate antisense oligonucleotides to protein kinase C (PKC) alpha inhibit proliferation in rat C6 glioma
79. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte‐macrophage colony‐stimulating factor stimulates potent, specific, and long‐lasting anti‐tumor immunity
80. The biochemistry and mechanism of action of acyclovir
81. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex viurs thymidine kinase gene
82. Adenovirus early region 4 is required for efficient virus particle assembly
83. Liposome encapsulation of retrovirus allows efficient superinfection of resistant cell lines
84. Wild‐type p53 activates transcription in vitro
85. Interleukin‐2 production by tumor cells bypasses T helper function in the generation of an antitumor response
86. A system for tissue‐specific gene targeting: Transgenic mice susceptible to subgroup A avian leukosis virus‐based retroviral vectors
87. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations
88. Lipofectin: A highly efficient, lipid‐mediated DNA transfection procedure
89. Expression of the neuroectodermal intermediate filament nestin in human melanomas.
90. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno‐associated virus promoter
91. An improved system for packaging recombinant adeno‐associated virus vectors capable of in vivo transduction
92. Tumor angiogenesis: therapeutic implications
93. Angiogenic factors
94. Angiogenesis in cancer, vascular, rheumatoid and other disease
95. The “bystander effect”: Tumor regression when a fraction of the tumor mass is genetically modified
96. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus‐mediated transfer of the wild‐type p53 gene
97. Temporal control of gene expression in transgenic mice by a tetracycline‐responsive promoter
98. A unique form of terminal redundancy in adenovirus DNA molecules
99. A defective HSV‐1 vector expresses Escherichia coli (‐galactosidase in cultured peripheral neurons
100. A system, using neural cell lines, to characterize HSV‐1 vectors containing genes which affect neuronal physiology, or neuronal promoters
101. A helper virus‐free packaging system for HSV‐1 plasmid vectors that supports efficient gene transfer in the rat brain
102. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosporamide mustard in the rat
103. Correlation of histolopathological features and proliferative potential of gliomas
104. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and embryos
105. Adrenergic regulation of intercellular communications between cultured striatal astrocytes from the mouse
106. Development of herpes simplex virus as a gene transfer vector for the central nervous system
107. Correspondence re: Z. Ram et al., In situ retroviral‐mediated gene transfer for the treatment of brain tumors in rats. Cancer Res, 53: 83–88, 1993
108. Herpes simplex virus type 1‐induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant
109. Tight control of gene expression in mammalian cells by tetracyclineresponsive promoters
110. Transcriptional activation by tetracyclines in mammalian cells
111. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
112. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo
113. The gap‐junctional protein connexin 43 is expressed in dermis and epidermis of human skin: differential modulation by retinoids
114. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff
115. The phagocytosis of rod outer segment is inhibited by drugs linked to cyclic adenosine monophosphate production
116. Colony stimulating factors, cytokines and monocyte‐macrophages ‐ some controversies
117. Active site mutations of Pseudomonas aeruginosa exotoxin A. Analysis of the His440 residue
118. Inhibition of adenovirus early region IV transcription in vitro by a purified viral DNA binding protein
119. An engineered PGK promoter and lac operator‐repressor system for the regulation of gene expression in mammalian cells
120. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retrovirus vector
121. An adenovirus early region 4 gene product is required for induction of the infection‐specific form of cellular E2F activity
122. Incidence of second primary tumors among childhood cancer survivors
123. Versatile retroviral vectors for potential use in gene therapy
124. Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome
125. Control of gene expression by oligodeoxynucleotide covalently linked to intercalating agents and nucleic acid‐cleaving reagents
126. The anti‐gene strategy: control of gene expression by triplex‐forming‐oligonucleotides
127. Regulation of the glial‐specific JC virus early promoter by the transcription factor Sp1
128. Amplicon‐based herpes simplex virus vectors
129. Altering central nervous physiology with a defective herpes simplex virus vector expressing the glucose transporter gene
130. The icosahedral form of an adenovirus
131. The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex
132. Retroviral‐mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy
133. In vivo antitumor activity of 5‐fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase
134. Metabolism of 5‐fluorocytosine to 5‐fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase
135. Liposomes for the transformation of eukaryotic cells
136. Anti‐synthetic peptide antibody reacting at the fusion junction of deletion‐mutant epidermal growth factor receptors in human glioblastoma
137. Mammalian artificial chromosomes: a new tool for gene therapy
138. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy
139. Involvement of IGF‐I and II ‐antisense expression in tumor differentiation and immunotherapy of rat brain glioblastoma and murine teratocarcinoma
140. Bradykinin selectively opens blood‐tumor barrier in experimental brain tumors
141. Intracarotid infusion of RMP‐7, a bradykinin analog: a method for selective drug delivery to brain tumors
142. Inhibition of thymidine kinase gene expression by anti‐sense RNA: a molecular approach to genetic analysis
143. Constitutive and conditional suppression of exogenous and endogenous genes by anti‐sense RNA
144. Adenovirus‐mediated in vivo gene transfer and expression in normal rat liver
145. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues
146. Selective destruction of gliomas in immunocompetent rats by thymidine kinase‐defective herpes simplex virus type 1
147. Cytotoxicity of a replication‐defective mutant of herpes simplex virus type 1
148. Improved cell survival by the reduction of immediate‐early gene expression in replication‐defective mutants of herpes simplex virus type 1 but not by mutation of the virion host shutoff function
149. An adenovirus type 5 early gene function regulates expression of other early viral genes
150. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats
151. Long‐term gene expression and phenotypic correction using adeno‐associated virus vectors in the mammalian brain
152. Tissue‐specific targeting of retroviral vectors through ligand‐receptor interactions
153. Participation of p53 protein in the cellular response to DNA damage
154. Identification of p53 as asequence‐specific DNA‐binding protein
155. Inhibition of cellular transformation by the adeno‐associated virus rep gene
156. Inhibition of vascular endothelial growth factor‐induced angiogenesis suppresses tumour growth in vivo
157. Selective enhancement by an antiviral agent of the radiation‐induced cell killing of human glioma cells transduced with HSV‐tk gene
158. The use of halogenated thymidine analogues as clinical radiosensitizers. Rationale, current status, and future prospects
159. The future of therapy for glioblastoma
160. Mapping and direct visualisation of a region‐specific viral DNA integration site on chromosome 19q13‐qter
161. The family of bacterial ADP‐ribosylating exotoxins
162. Wild‐type p53 is a cell‐cycle checkpoint determinant following irradiation
163. Immunobiology of malignant astrocytomas
164. GM‐CSF enhances 3F8 monoclonal antibody‐dependent cellular cytotoxicity against human melanoma and neuroblastoma
165. Adeno‐associated virus gene expression inhibits cellular transformation by heterologous genes
166. Inhibition of tumor growth by antisense transforming growth factor alpha (TGF alpha) expression in a spontaneously transformed rat liver oval cell line
167. Endothelial cell implantation and survival within experimental gliomas
168. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
169. Effects of deletions in adenovirus early region 1 genes upon replication of adeno‐associated virus
170. An adenovirus vector for gene transfer into neurons and glia in the brain
171. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus
172. Human immunodeficiency virus infection of cells arrested in the cell cycle
173. Stable high‐level gene expression in mammalian cells by T7 phage RNA
174. The octamer‐binding protein Oct‐2 represses HSV immediate‐early genes in cell lines derived from latently infectable sensory neurons
175. Growth arrest induced by wild‐type p53 protein blocks cells prior to or near the restriction point in late G1 phase
176. An avian oncovirus mutant (SE 21Q1b) deficient in the genomic RNA: biological and biochemical characterization
177. Radisurgery as part of the initial management of patients with malignant gliomas
178. The cell‐cell channel in the control of growth
179. p53‐dependent apoptosis modulates the cytotoxicity of anticancer agents
180. p53 status and the efficacy of cancer therapy in vivo
181. Herpes simplex virus 1 (HSV‐1) helper co‐infection affects the distribution of an amplicon encoded protein in glia
182. The N‐terminal alpha‐helix of fragment B of diphtheria toxin promotes translocation of fragment A into the cytoplasm of eukaryotic cells
183. Immunobiology of primary intracranial tumors. I. Studies of the cellular and humoral general immune competence of brain tumor patients
184. National survey of patterns of care for brain tumor patients
185. Specific hybridization arrest of dihydrofolate reductase mRNA in vitro using antisense RNA or anti‐sense oligonucleotides
186. Inhibition of angiogenesis by recombinant human platelet factor‐4 and related peptides
187. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity
188. Expanded spectrum of viral therapy in the treatment of nervous system tumors
189. Reduction and elimination of encephalitis in an experimental glioma model with attenuated herpes simplex mutants that retain susceptibility to acyclovir
190. Construction and use of a safe and efficient amphotropic packaging cell line
191. Experimental therapy of human glioma by means of a genetically engineered virus mutant
192. G207: a multiple deletion herpes mutant for brain tumor therapy
193. Expression of diphtheria toxin A‐chain in mature B‐cells: a potential approach to therapy of B‐lymphoid malignancy
194. Sequences required for the coordinate induction of the AAV p19 and p40 promoters by the Rep protein
195. How DNA viruses perturb MHC expression to alter immune recognition
196. Negative growth regulation in a glioblastoma tumor cell line that conditionally express human wild‐type p53
197. Cell cycle effects of microinjected antisense oligodeoxynucleotides to p34cdc2 kinase
198. Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro
199. Strategies to achieve gene delivery via the receptor‐mediated endocytosis pathway
200. High affinity VEGF‐binding and developmental expression suggests flk‐1 as a major regulator of vasculogenesis and angiogenesis
201. Glioblastoma growth inhibited in vivo by a dominant‐negative Flk‐1 mutant
202. Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus
203. Treatment of malignant gliomas using ganciclovir‐hypersensitive, ribonucleotide reductase‐deficient herpes simplex viral mutant
204. Selective expression of foreign genes in glioma cells: use of the mouse myelin basic protein gene promoter to direct toxic gene expression
205. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: a paradigm for a prospective cancer control strategy
206. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors
207. Inhibitors of angiogenesis
208. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts
209. Retrovirally transduced Escherichia coli gpt genes combine selectability with chemosensitivity capable of mediating tumor eradication
210. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5‐fluorocytosine: A negative selection system
211. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5‐Fluorocytosine and induce protective immunity to wild type tumor
212. Selection for animal cells that express the Escherichia coli gene coding for xanthineguanine phosphoribosyltransferase
213. Use of adeno‐associated virus as a general transduction vector for mammalian cells
214. Ultrastructural analysis of gap junctions in C6 glioma cells transfected with connexin43 cDNA
215. Biologically active, recombinant DNA in clathrin‐coated vesicles isolated from rat livers after in vivo injection of liposome‐encapsulated DNA
216. An adenovirus E4 gene product trans‐activates E2 transcription and stimulates stable E2F binding through a direct association with E2F
217. Modification of the blood‐brain barrier in the chemotherapy of malignant brain tumors
218. Mechanisms of activation of early viral transcription by the adenovirus E1A gene product
219. Regulation of early adenovirus transcription: a protein product of early region 2 specifically represses region 4 transcription
220. Specific inhibition of c‐sis protein synthesis and cell proliferation with antisense oligodeoxynucleotides in human glioma cells
221. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector
222. Gene therapy for the treatment of brain tumors using intra‐tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
223. Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study
224. Effects of transforming growth factor‐beta 1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells
225. Chromosome damage induced by herpes simplex virus type 1 in an early infection
226. Adenovirus‐mediated gene therapy of experimental gliomas
227. Virus‐receptor interaction in an adenovirus system
228. Selective cytotoxicity of hapten‐substituted cells with an antibody‐enzyme conjugate
229. In vitro killing of melanoma by liposome‐delivered intracellular irradiation
230. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo
231. Up‐regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis
232. Molecular mechanisms of developmental and tumor angiogenesis
233. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms
234. Mode of action studies. B. Target nucleic acid synthesis and cell division. I. 5‐Fluorocytosine
235. Brain, other central nervous system, and eye cancer
236. Brain tumors in children
237. Antimetastatic vaccination of tumor‐bearing mice with two types of IFN‐gamma geneinserted tumor cells
238. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
239. Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system
240. Efficient adenovirus‐mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice
241. Toxicity studies of retroviral‐mediated gene transfer for the treatment of brain tumors
242. In situ retroviral‐mediated gene transfer for the treatment of brain tumors in rats
243. In vivo transfer of the human interleukin‐2 gene: negative tumoricidal results in experimental brain tumors
244. Summary of results and conclusions of the gene therapy of malignant brain tumors: Clinical study
245. Transferrin receptor in normal and neoplastic brain tissue: implications for brain‐tumor immunotherapy
246. Transfection with bFGF sense and anti‐sense cDNA resulting in modification of malignant glioma growth
247. Anti‐oncogenic activity of signalling‐defective epidermal growth factor receptor mutants
248. Identification of a protein linked to the ends of adenovirus DNA
249. A circular DNA‐protein complex from adenoviruses
250. Suppression of single and double nonsense mutations introduced into the diphtheria toxin A‐chain gene: a potential binary system for toxin gene therapy
251. Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function
252. Retinoid‐enhanced gap junctional communication is achieved by increased levels of connexin 43 mRNA and protein
253. Genetic engineering of novel genomes of large DNA viruses
254. herpes viruses and their replication
255. MR and cognitive testing of patients undergoing osmotic blood‐brain barrier disruption with intra‐arterial chemotherapy
256. Gene transfer into medulloblastoma leptomeningeal xenografts: a potential therapeutic modality
257. Use of retroviral vectors for the delivery of antisense constructs
258. Modulation of T cell function by gliomas
259. Accumulation of wildtype p53 protein in human astrocytomas
260. Transformation‐dependent expression of interleukin genes delivered by a recombinant parvovirus
261. Immunotherapy of bladder cancer with cytokine gene‐modified tumor vaccines
262. “Bystander killing” induces apoptosis and is inhibited by forskolin
263. Cloning of adeno‐associated virus into pBR322: rescue of intact virus from the recombinant virus in human cells
264. Helper‐free stocks of recombinant adeno‐associated viruses: normal integration does not require viral gene expression
265. Adeno‐associated virus: integration at a specific chromosomal locus
266. Safety and short‐term toxicity of a novel cationic lipid formulation for human gene therapy
267. Adenovirus early region 1B 58,000‐dalton tumor antigen is physically associated with an early region 25,000‐dalton protein in productively infected cells
268. Long‐term in vivo expression of retrovirus ‐mediated gene transfer in mouse fibroblast implants
269. Nonviral approaches to gene therapy
270. Adenovirus‐dependent release of choline from plasma membrane vesicles at an acidic pH is mediated by the penton base protein
271. Evidence that the penton base of adenovirus is involved in potentiation of toxicity of Pseudomonas exotoxin conjugated to epidermal growth factor
272. Role of a low‐pH environment in adenovirus enhancement of the toxicity of a Pseudomonas exotoxin‐epidermal growth factor conjugate
273. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells
274. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line
275. Interleukin‐2 gene therapy in a patient with glioblastoma
276. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli deoD gene to generate toxic purines
277. The herpes simplex virus amplicon: A new eucaryotic defective‐virus cloning‐amplifying vector
278. The herpes simplex virus amplicon: A new eucaryotic defective‐virus cloning‐amplifying vector
279. Detection of herpes simplex virus type 1 transcripts during latent infection in mice
280. Potential pitfalls in in vitro activity testing of free and liposome‐entrapped doxorubicin
281. Antitumor effects of interleukin‐12 (IL‐12): applications for the immunotherapy and gene therapy of cancer
282. Gene expression of fibroblast growth factors in human gliomas and meningeomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissue
283. Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor
284. Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1‐thymidine kinase gene and wild type retrovirus kills other tumor cells
285. An experimental model of retrovirus gene therapy for malignant brain tumors
286. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection
287. Protamine is an inhibitor of angiogenesis
288. Adeno‐associated virus (AAV) as a vector for gene transfer into glial cells of the human central nervous system
289. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor
290. Impaired cell‐mediated immunity in human brain tumors
291. Partial protection of oncogene, anti‐sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups
292. RG‐2 glioma growth attenuation and severe brain edema caused by local production of interleukin‐2 and interferon‐2
293. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin‐like growth factor 1 RNA
294. Retrovirus‐mediated gene transfer in cancer therapy
295. Modifications in the binding domain of avian Retrovirus envelope protein to redirect the host range of retroviral vectors
296. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells
297. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild‐type p53 alleles to glioblastoma cells
298. Replication of retroviruses
299. Age curves of central nervous system tumor incidence in adults: variation of shape by histologic type
300. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines
301. Efficient gene transfer with adeno‐associated virus‐based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer
302. Long‐term correction of mouse dystrophic degeneration by adenovirus‐mediated transfer of a minidystrophin gene
303. Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells
304. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme
305. Astrocytic gliomas: Characterization on a molecular genetic basis
306. Influenza virus haemagglutinin HA‐2 N‐terminal fusogenic peptides augment gene transfer by transferrin‐polylysine‐DNA complexes: towards a synthetic virus‐like gene transfer vehicle
307. Regulated high level expression of a human gamma‐globin gene introduced into erythroid cells by an adeno‐associated virus vector
308. Experimental tumor therapy in mice using the cyclophosphamide‐activating cytochrome P450 2B1 gene
309. Virus vector‐mediated transfer of drug‐sensitivity genes for the treatment of experimental brain tumors
310. Enhancement of Interleukin‐4‐mediated tumor regression in athymic mice by in situ retroviral gene transfer
311. The 9L rat brain tumor: description and application of an animal model
312. Stability, Clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system
313. Human promyelocytic leukaemia HI‐60 cell proliferation and c‐myc protein expression are inhibited by antisense penta‐decadeoxynucleotide targeted against c‐myc mRNA
314. Expression of human adenosine deaminase in mice reconstituted with retrovirus‐transduced hematopoietic stem cells
315. Monocyte chemoattractant protein 1 acts as a T‐lymphocyte chemoattractant
316. Direct gene transfer into mouse muscle in vivo
317. Adenovirus‐2 DNA contains an inverted terminal repetition
318. Gap junctions in rabbit corneal epithelium: limited permeability and inhibition by cAMP
319. Inflammatory effects of gene transfer into the CNS with defective HSV‐1 vectors
320. Bystander tumoricidal effect in the treatment of experimental brain tumors
321. LM and EM immunolocalization of the gap junctional protein connexin 43 in rat brain
322. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment
323. Cellular immunity to viral antigens limits E1‐deleted adenovirus for gene therapy
324. Gene expression from transcriptionally disabled retroviral vectors
325. Wild‐type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin‐6
326. Simple method to prepare cationic multilamellar liposomes for efficient transfection of human interferon‐B gene to human glioma cells
327. Estimation of growth fraction with bromodeoxyuridine in human central nervous system tumors
328. Treatment of glioma by engineered interleukin 4‐secreting cells
329. Adenovirus‐mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis
330. DNAase 1 encapsulated in liposomes can induce neoplastic transformation of Syrian hamster embryo cells in culture
331. Retroviral vector‐mediated transduction of K‐ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype
332. Construction and characterization of retroviral vectors expressing biologically active human interleukin‐12
333. Pharmacological considerations